Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Essential thrombocythemia--clinical course from personal material]

M Bieniaszewska1, A Hellmann, J Kabata

  • 1Kliniki Hematologii I.Ch.W., Akademii Medycznej w Gdańsku.

Polskie Archiwum Medycyny Wewnetrznej
|August 1, 1994
PubMed
Summary

This study on essential thrombocythemia found that platelet counts between 900-1900 x 10(9)/l increase thrombotic risk, while counts over 1900 x 10(9)/l raise hemorrhage risk. Treatment strategies vary by platelet level and symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ureteric Stenting in Kidney Transplant Recipients, Gdansk Centre Experience, Poland.

Transplantation proceedings·2018
Same author

[Expenditure on the Care of COPD Patients Under Everyday Conditions in Pneumological Practices Differentiated According to Patients in Chronic Care and New Patients and Severity of the Illness].

Pneumologie (Stuttgart, Germany)·2017
Same author

[Positionpaper on Telemonitoring in Sleep-Related Breathing Disorders].

Pneumologie (Stuttgart, Germany)·2017
Same author

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Leukemia·2017
Same author

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Leukemia·2016
Same author

[Cannabis--Position Paper of the German Respiratory Society (DGP)].

Pneumologie (Stuttgart, Germany)·2016

Area of Science:

  • Hematology
  • Oncology

Context:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Clinical management of ET requires careful consideration of bleeding and thrombotic risks.

Purpose:

  • To analyze the clinical course of essential thrombocythemia in a cohort of 17 patients.
  • To correlate platelet levels with the incidence of hemorrhagic and thrombotic complications.
  • To guide treatment strategies based on specific platelet count thresholds.

Summary:

  • The study analyzed 17 ET patients (age 29-82) diagnosed using Polycythemia Vera Study Group criteria, with a mean platelet count of 1680 x 10(9)/l.
  • Hemorrhagic complications occurred in 42% and thrombotic events in 35%; 5 patients were asymptomatic.
  • Platelet counts between 900-1900 x 10(9)/l indicate a risk for thrombosis, suggesting antiaggregation therapy.

Related Experiment Videos

  • Counts exceeding 1900 x 10(9)/l increase hemorrhage risk, contraindicating antiaggregation and favoring thrombocytapheresis.

    • Impact:

    • Provides evidence-based recommendations for managing essential thrombocythemia based on platelet counts.
    • Highlights the importance of individualized treatment approaches to mitigate complications.
    • Informs clinical decision-making regarding antiaggregation therapy versus thrombocytapheresis.